Expert Opinion on Investigational Drugs

Papers
(The TQCC of Expert Opinion on Investigational Drugs is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
SGLT2 inhibitors: an evidence-based update on cardiovascular implications106
Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development80
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology77
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?75
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials74
Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia71
Theranostic strategies in sarcoma: preliminary clinical evidence62
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development61
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy56
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies53
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases53
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval51
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy44
Management of inflammaging in kidney diseases: focusing on the current investigational drugs43
Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials41
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?41
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome37
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials37
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?35
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease33
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis32
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential31
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies27
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials27
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets26
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors26
Investigational drugs for the treatment of dysmenorrhea26
Emerging treatments for chronic urticaria22
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development22
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su22
Ewing sarcoma: investigational mono- and combination therapies in clinical trials21
Potassium channel modulators and schizophrenia: an overview of investigational drugs21
Recent developments in adjunct therapies for type 1 diabetes21
Investigational drugs for immune thrombocytopenia21
IgA nephropathy: an overview of drug treatments in clinical trials20
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia20
Current options and investigational drugs for the treatment of eosinophilic esophagitis19
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer19
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials19
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics18
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer17
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development17
Duchenne muscular dystrophy: promising early-stage clinical trials to watch16
What is the progress of experimental drug development for fibromyalgia?16
Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study15
Novel systemic treatment approaches for metastatic pancreatic cancer15
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration15
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options15
Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-115
Investigational new drugs for the treatment of leishmaniasis15
Frontotemporal dementia: from genetics to therapeutic approaches15
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists14
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer14
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal14
Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials14
Current experimental and early investigational agents for cardiac fibrosis: where are we at?14
NF1 alterations in cancers: therapeutic implications in precision medicine14
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects13
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations13
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents13
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease13
Assessing the clinical progress of the bispecific nanobody sonelokimab13
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)13
Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 202113
Navafenterol for chronic obstructive pulmonary disease therapy12
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa12
Progress in the treatment of anal cancer: an overview of the latest investigational drugs12
Investigational drugs for the treatment of olfactory dysfunction12
Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials11
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions11
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)11
Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps11
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici11
Low-dose aspirin for early COVID-19: does the early bird catch the worm?11
JAK inhibitors for rheumatoid arthritis10
Inflammatory myopathies: shedding light on promising agents and combination therapies in clinical trials10
Emerging neuroprotective interventions in periventricular leukomalacia - A systematic review of preclinical studies10
Pharmacological agents for bone fracture healing: talking points from recent clinical trials10
Inflammation and Huntington’s disease – a neglected therapeutic target?10
JAK inhibitors in crohn’s disease: ready to go?10
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents10
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study10
Camrelizumab: an investigational agent for hepatocellular carcinoma10
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia10
Immunotherapeutic strategies for treating opioid use disorder and overdose10
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus10
Investigational new drugs for the treatment of Dravet syndrome: an update10
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies9
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials9
New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine9
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs9
Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials9
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers9
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections9
Assessing potential of psilocybin for depressive disorders9
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension9
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid recep9
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis9
Emerging agents for the treatment and prevention of stroke: progress in clinical trials9
Investigational anti IL-13 asthma treatments: a 2023 update9
The impact of current investigational drugs for acne on future treatment strategies9
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress9
0.059067010879517